Aim: To build on the previous article and further explore the safety and efficacy of robotic-assisted laparoscopic prostatectomy (RALP) in the first 100 cases from a single institution in New Zealand.
Method: A prospective database was created to monitor perioperative and postoperative outcomes of men undergoing RALP for clinically localised carcinoma of the prostate.
Results: The first 100 cases were followed prospectively with a mean follow-up of 13.9 months. There were no conversions to open surgery, or re-operations. Average blood loss was 281 ml, and there was only one blood transfusion. Mean hospital stay was 1.1 nights. Mean console time improved from 251.4 minutes over the first 10 cases to 104.6 minutes over the last 10. The overall positive margin rate was 18%. The positive margin rate from pT2 tumours was 8%. The majority of patients had well-differentiated, organ-confined disease. Postoperatively, five have a detectable PSA level. 68% use no incontinence pads at 12 months. At one year, 12% of the men who were previously fully potent have achieved full potency again without assistance
Conclusion: The results further support RALP as a safe, effective, and well tolerated procedure for the management of carcinoma of the prostate. The early local experience compares favourably with other published early series.
Download full-text PDF |
Source |
---|
Sci Rep
January 2025
Department of Urology, Kyoto University School of Medicine, 54 Shougoinkawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
This study evaluated the impact of aspirin on the biochemical recurrence (BCR) rate following robot-assisted radical prostatectomy (RARP) in patients. A database search identified patients who underwent RARP for pT2-3N0M0 disease at any of 25 centers between 2011 and 2022, categorized into aspirin (n = 350) and control groups (n = 5857). Adjustment by 1:1 propensity score matching (PSM) and Mahalanobis distance matching (MDM) created 350 matched pairs.
View Article and Find Full Text PDFUrology
January 2025
Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China; Institute of Urologic Disease, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China. Electronic address:
Objectives: To explore new metrics for assessing radical prostatectomy difficulty through a two-stage deep learning method from preoperative magnetic resonance imaging.
Methods: The procedure and metrics were validated through 290 patients consisting of laparoscopic and robot-assisted radical prostatectomy procedures from two real cohorts. The nnUNet_v2 adaptive model was trained to perform accurate segmentation of the prostate and pelvis.
Cancers (Basel)
December 2024
Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, 00185 Rome, Italy.
: Robot-assisted radical prostatectomy (RARP) for the treatment of prostate cancer (PCa) has been standardized over the last 20 years. At our institution, only n = 3 rob arms are used for RARP. In addition, n = 2, 12 mm lap trocars are placed for the bedside assistant symmetrically at the midclavicular lines, which allows for direct pelvic triangulation and greater involvement of the assisting surgeon.
View Article and Find Full Text PDFBMC Urol
January 2025
Department of Urology, Peking University Third Hospital, Haidian District, Beijing, 100191, P.R. China.
Background: To propose the bladder mucosal smoothness (BMS) grade and validate a predictive model including MRI parameters preoperatively that can evaluate the early recovery of urinary continence (UC) after laparoscopic radical prostatectomy (LRP).
Methods: A retrospective analysis was conducted on 203 patients (83 patients experienced UI at the three-month follow-up) who underwent LRP in our medical center and were diagnosed with prostate cancer (PCa) from June 2016 to March 2020. Patients' clinicopathological data were collected.
Int J Urol
January 2025
Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!